

# Caroline Nothdurfter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12069788/publications.pdf>

Version: 2024-02-01

31  
papers

1,450  
citations

430874

18  
h-index

477307

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

2239  
citing authors

#	ARTICLE	IF	CITATIONS
1	Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects. <i>Science</i> , 2009, 325, 490-493.	12.6	299
2	The role of allopregnanolone in depression and anxiety. <i>Progress in Neurobiology</i> , 2014, 113, 79-87.	5.7	227
3	Translocator protein (18 kDa) (TSPO) is expressed in reactive retinal microglia and modulates microglial inflammation and phagocytosis. <i>Journal of Neuroinflammation</i> , 2014, 11, 3.	7.2	177
4	The Role of Chemokines in the Pathophysiology of Major Depressive Disorder. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2283.	4.1	94
5	Differential effects of TSPO ligands on mitochondrial function in mouse microglia cells. <i>Psychoneuroendocrinology</i> , 2019, 106, 65-76.	2.7	57
6	Neuroactive Steroids as Endogenous Modulators of Anxiety. <i>Current Pharmaceutical Design</i> , 2008, 14, 3525-3533.	1.9	52
7	Translocator protein (18 kDa) (TSPO) as a therapeutic target for anxiety and neurologic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 107-112.	3.2	49
8	The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 162-170.	2.6	46
9	The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: A randomized trial. <i>Journal of Psychiatric Research</i> , 2014, 53, 76-83.	3.1	45
10	CRISPR-Cas9 Mediated TSPO Gene Knockout alters Respiration and Cellular Metabolism in Human Primary Microglia Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3359.	4.1	45
11	The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 82-90.	2.6	41
12	Impact of Lipid Raft Integrity on 5-HT <sub>3</sub> Receptor Function and its Modulation by Antidepressants. <i>Neuropsychopharmacology</i> , 2010, 35, 1510-1519.	5.4	36
13	Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression. <i>Psychoneuroendocrinology</i> , 2014, 39, 141-151.	2.7	35
14	Lipid raft integrity affects GABA <sub>A</sub> receptor, but not NMDA receptor modulation by psychopharmacological compounds. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1361-1371.	2.1	29
15	Major Depressive Disorder is Associated with Impaired Mitochondrial Function in Skin Fibroblasts. <i>Cells</i> , 2020, 9, 884.	4.1	28
16	The cytokine IL-17A as a marker of treatment resistance in major depressive disorder?. <i>European Journal of Neuroscience</i> , 2021, 53, 172-182.	2.6	24
17	Recent Developments in Potential Anxiolytic Agents Targeting GABA <sub>A</sub> /BzR Complex or the Translocator Protein (18kDa) (TSPO). <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 360-370.	2.1	21
18	Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: An open-label study. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 390-399.	2.6	19

#	ARTICLE	IF	CITATIONS
19	Effects of genetic variants in the TSPO gene on protein structure and stability. <i>PLoS ONE</i> , 2018, 13, e0195627.	2.5	19
20	Macrophage-Derived Chemokine: A Putative Marker of Pharmacological Therapy Response in Major Depression?. <i>NeuroImmunoModulation</i> , 2017, 24, 106-112.	1.8	17
21	The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 447-456.	2.6	16
22	Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamicâ€“pituitaryâ€“adrenal-axis activity in relation to antidepressant effectiveness. <i>Journal of Psychiatric Research</i> , 2014, 52, 15-20.	3.1	15
23	Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with Recovery from Major Depressive Disorder and Related Neurocognitive Impairment. <i>NeuroImmunoModulation</i> , 2020, 27, 152-162.	1.8	13
24	Identification of a Domain which Affects Kinetics and Antagonistic Potency of Clozapine at 5-HT3 Receptors. <i>PLoS ONE</i> , 2009, 4, e6715.	2.5	12
25	Lack of association of the 5-HT <sub>3A</sub> receptor with schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 310-315.	1.7	8
26	Pitfalls in isolating lipid rafts. <i>Nature Reviews Neuroscience</i> , 2007, 8, 567-567.	10.2	6
27	Dissociation of endocrine responses to the Trier Social Stress Test in Virtual Reality (VR-TSST) by the benzodiazepine alprazolam and the translocator protein 18kDa (TSPO) ligand etifoxine. <i>Psychoneuroendocrinology</i> , 2021, 124, 105100.	2.7	5
28	Computer-Assisted Avatar-Based Treatment for Dysfunctional Beliefs in Depressive Inpatients: A Pilot Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 608997.	2.6	5
29	Induced neural progenitor cells and iPSC-neurons from major depressive disorder patients show altered bioenergetics and electrophysiological properties. <i>Molecular Psychiatry</i> , 0, , .	7.9	5
30	A novel dual mode-of-action anti-hyperalgesic compound in rats which is neuroprotective and promotes neuroregeneration. <i>European Journal of Pharmacology</i> , 2022, 923, 174935.	3.5	4
31	Differential effects of the translocator protein 18kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment. <i>Psychopharmacology</i> , 2022, , 1.	3.1	0